Gufic Biosciences Limited has launched Botulinum Toxin Type A injection ‘Zarbot’, developed and manufactured in collaboration with USA-based Prime Bio.
Mumbai, 30th December 2022: Reiterating its commitment to Make in India, Gufic Biosciences Limited (“Gufic”) a fast-growing pharmaceutical player recognized for its innovative, high-quality pharmaceutical and herbal products has launched indigenously produced ‘Zarbot’ (Botulinum Toxin Type A) injection in India.
‘Zarbot’ was unveiled by Dr. Dirk Dressler, Dr. Balaram Singh and several other prominent Healthcare Practitioners of India in a well-attended event held in Mumbai. ‘Zarbot’ has been developed and manufactured in collaboration with USA-based Prime Bio. One of the most important USPs of ‘Zarbot’ is that it has been manufactured using purified HALL strain and proprietary technology which results in thin film formulation and better stability compared to other botulinum toxin brands.
Speaking on the occasion, Dr. Rajesh Lalchandani, Consultant Medical Director said, “Illustrating our continued commitment to bring out the best possible treatment for the people suffering from neurological deficits in India, we have launched Botulinum Toxin Type A injection ‘Zarbot’. With its biological potency similar to international brands ‘Zarbot’ complies with European and British Pharmacopeial standards.”
‘Zarbot’ is an effective option for treating certain neurological conditions which can be more challenging with conventional therapy. It comes in a unique pack with 10 ml Normal saline to improve compliance and can be stored at 2-8 °C for 36 months or 25 °C for 6 months before reconstitution and also stable up to 14 days at 2-8 °C after reconstitution and multiple withdrawal of injection solution from vial under aseptic precautions.
The event thronged by the key opinion leaders from across the globe also witnessed the launch of the first state-of-the-art Centre of Excellence for Botulinum Toxin in India by Gufic. Currently only limited healthcare Practitioners in India are well versed in injection technique of Botulinum Toxin. In this backdrop the Centre of excellence launched by Gufic will offer training to Healthcare Practitioners on techniques of delivering complex injectable products like Botulinum Toxin.
Gufic is well-recognised as one of the largest manufacturers of Lyophilized injections in India and its lyophilized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments, among others. The products of Gufic Biosciences are supplied to all the major hospital chains and leading medical facilities.
Gufic is engaged in the research and development, manufacturing, marketing, distribution and sale of pharmaceutical and allied products. Gufic is known and respected for innovative and high quality pharmaceutical and herbal products along with a wide range of Active Pharmaceutical Ingredients (APIs). Gufic is one of the fastest growing company among the top 100 pharma companies in India and is also one of the largest manufacturers of Lyophilized injections in India and have a fully automated lyophilisation plant. Gufic’s lyophilized products are available in Therapy areas like Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor (PPI). Gufic is now augmenting its global focus by deepening its presence in the priority markets of India, Germany, Switzerland, South Africa, Russia, Canada, Europe and other key countries within the emerging market territories. Gufic aims at providing lifesaving drugs to people at affordable prices with no compromise in its quality. Gufic is a WHO-GMP, EU GMP, ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP, Australia TGA, Colombia INVIMA and Uganda NDA approved company with a total capacity of 30 million lyophilized vials per annum.